Incidence, prevalence and burden of Dry Eye diseAse in France (IDEA)

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation

  Healthcare resource utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  Dry eye

Population studied

• Short description of the study population:
  Subjects with dry eye disease (DED) identified from the French nationwide claims database (SNDS).
• Age groups:
  Term newborn infants (0 – 27 days)

  Infants and toddlers (28 days – 23 months)

  Children (2 to < 12 years)

  Adolescents (12 to < 18 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Patients with dry eye disease
• Estimated number of subjects:
  10000

Study design details

• Main study objective:
  The main objective is to estimate the DED prevalence and incidence in France in 2014 and 2015.
• Data analysis plan:
  The following analyses will be performed:- A flow chart and an attrition table depicting the number of patients identified in the database- Description of patient baseline demographics and clinical characteristics, according to prevalent/incident status and DED severity level- Estimation of the annual prevalence and incidence of DED in 2014 and 2015 in the French population. Prevalence by DED severity level will also be computed- Description of treatment pattern at the index date (stratified on incident/prevalent status and DED severity level), and during the follow-up period (stratified on DED severity only)- Description of the disease evolution (switch between DED severity levels over the follow-up period and duration of severity stages)- Description of healthcare resource use and costs for one and two years from the National Health Insurance perspective and for the collective perspective stratified by DED severity level